gavilimomab

chemical compound

Uses your system voice; voice and rate in settings.

Q3758982Snapshot

≈ 1 min read

Names in other languages

  • العربيةغافيليموماب
  • Englishgavilimomab
  • Françaisgavilimomab
  • ItalianoGavilimomab
  • NederlandsGavilimomab
  • Tiếng ViệtGavilimomab

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147. Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy. It was originally developed by Abgenix, which was later acquired by Amgen.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1177181286 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.